Cardiology Associates First In Mobile To Perform Novel AF Treatment

Dr. Chance Witt of Cardiology Associates has performed the first treatment using the Medtronic PulseSelect Pulsed Field Ablation (PFA) System to treat atrial fibrillation (AF) in Mobile. The PFA system is a breakthrough technology that uses pulsed electric fields to treat patients with paroxysmal or persistent AF. Recently approved by the U.S. Food and Drug Administration, the PulseSelect PFA system can effectively, efficiently and safely treat both paroxysmal and persistent AF. Ablation, a common treatment option for those with AF, targets the cause of irregular heart rhythms by creating scar tissue and can cause unwanted injury to surrounding tissues. The use of pulsed electric fields through an ablation catheter offers a novel, nonthermal approach by targeting heart tissue to interrupt irregular pathways in the heart and avoid unwanted injury to surrounding tissues. Cardiology Associates has a team of five subspecialty-trained cardiac electrophysiologists treating heart rhythm disorders such as AF.

Read More

USA Health Adds Oakes To Infectious Disease Division

USA Health Adds Oakes To Infectious Disease Division

Mobile Infirmary Cuts Ribbon On Maternal-Fetal Telemedicine Clinic

Mobile Infirmary Cuts Ribbon On Maternal-Fetal Telemedicine Clinic

USA Health’s Fox Elected ASHS Board Chair

USA Health’s Fox Elected ASHS Board Chair

Hellmich Named Outstanding ACE Mayor

Hellmich Named Outstanding ACE Mayor

McNair Joins Delta Policy, Bloom Groups

McNair Joins Delta Policy, Bloom Groups

CACC Names Academic Leader

CACC Names Academic Leader

Giggles And Glam Salon Breaks Ground In Daphne

Giggles And Glam Salon Breaks Ground In Daphne

White-Spunner Construction Announces Promotions

White-Spunner Construction Announces Promotions

Bowling For Books Coming To Eastern Shore Lanes

Bowling For Books Coming To Eastern Shore Lanes

Subscribe to our weekly newsletter

Sign up here for free to get Bay Business News email newsletter every Friday.

By subscribing, you agree to our User Agreement and Privacy Policy & Cookie Statement.

Something went wrong. Please check your entries and try again.